1) Pulmonary function in stable chronic heart failure (CHF). 2) COPD prevalence, underdiagnosis and overdiagnosis in stable CHF patients and its independent predictors. 3) Systemic inflammation in COPD and stable CHF: is there a synergistic effect?

1) Pulmonary function in stable chronic heart failure (CHF). 2) COPD prevalence, underdiagnosis and overdiagnosis in stable CHF patients and its independent predictors. 3) Systemic inflammation in COPD and stable CHF: is there a synergistic effect? - Pulmonary function, COPD and systemic inflammation in CHF.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33134

Enrollment

369

Registered

2009-09-10

Start date

2009-10-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemische inflammatie chronic bronchitis/emphysema COPD

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: ·Stable chronic heart failure patients with left ventricular systolic dysfunction (LVEF 15 and LVEF > 50%) ·Outpatients ·NYHA class I-IV ·18 years and older ·Informed consent

Exclusion criteria

Exclusion criteria: ·Patients who do not meet the inclusion criteria ·Patients who are not able to cooperate or undergo pulmonary function tests ·Other diseases that can lead to obstructive lung function: asthma, cystic fibrosis ·Disorders/diseases that can lead to restrictive lung function: oPulmonary: lung surgery (lobectomy/pneumectomy), parenchymal neoplasms, interstitial lung disease, sarcoidosis, pneumoconioses, lung abscess, lobar pneumonia, post-infectious scarring, atelectasis, radiation fibrosis oPleural: diffuse pleural thickening, mesothelioma, pleural effusion, pneumothorax oNeuromuscular diseases: ALS, poliomyelitis, myopathy, bilateral diaphragmatic paralysis, high spinal cord lesions, myasthenia gravis oAbdominal: obesity (BMI > 35) oPericardial: major pericardial effusion oLarge mediastinal processes oCollagenvascular diseases ·Malignancy with bad prognosis (survival

Design outcomes

Primary

Measure	Time frame
Primary study parameters/outcome of the study: 1) Lung function abnormalities in stable CHF, 2) COPD prevalence, under- and overdiagnosis, 3) systemic inflammation (hs-CRP, leukocytes, platelets, fibrinogen, TNF-a, IL-6).	—

Secondary

Measure	Time frame
Secondary study parameters/outcome of the study: 1) Predictors of COPD in CHF, 2) systemic inflammation after conventional COPD treatment: hs-CRP, leukocytes, platelets, fibrinogen, TNF-a, IL-6, 3) association between inflammatory markers and various patient characteristics, 4) lung function abnormalities after conventional COPD treatment, 5) Quality of life and dyspnoea before and after conventional COPD treatment.	—

Measure

Time frame

Secondary study parameters/outcome of the study: 1) Predictors of COPD in CHF, 2) systemic inflammation after conventional COPD treatment: hs-CRP, leukocytes, platelets, fibrinogen, TNF-a, IL-6, 3) association between inflammatory markers and various patient characteristics, 4) lung function abnormalities after conventional COPD treatment, 5) Quality of life and dyspnoea before and after conventional COPD treatment.

—

Countries

Netherlands

Outcome results